Related Experiment Video
Updated: Jan 7, 2026
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Levodopa exerts neuroprotective effects by suppressing microglial proinflammatory activation in a rat
Noriyuki Miyaue1, Mohammed E Choudhury2,3, Ikuko Takeda4,5
1Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan.
Abstract:
Levodopa is a central medicine used for the treatment of Parkinson's disease (PD) as a dopamine (DA) precursor that increases DA levels in the striatum. Microglia, resident macrophages in the brain, become activated in response to the progressive degeneration of nigral dopaminergic neurons in PD pathology, while releasing proinflammatory mediators that are harmful to dopaminergic neurons. DA has been shown to prevent proinflammatory activation of microglia. This study showed that DA decreases lipopolysaccharide-induced proinflammatory reactions and increases tissue repairing factors of microglia in cultured rat microglia. Levodopa was administered to 6-hydroxydopmaine (6-OHDA)-induced PD model rats for 7 days, and motor deficits were evaluated after a two-week withdrawal period. The levodopa-treated PD model rats showed a better motor function than the vehicle-treated rats. The administration of levodopa for 7 days led to an increase in DA levels and a suppression of microglial activation in the striatum, which was maintained, even at two weeks after withdrawal. These results suggest that levodopa may act in the PD brain, not only as a DA precursor, but also as an immunosuppressant to reduce neuroinflammation accompanied by PD pathology.
Insights
Levodopa, a Parkinson's disease treatment, boosts dopamine and reduces brain inflammation by suppressing microglia activation. This effect persists even after treatment stops, suggesting a dual role in Parkinson's therapy.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Parkinson's disease (PD) involves neuroinflammation driven by activated microglia.
- Dopamine (DA) depletion is central to PD, while DA can inhibit microglial activation.
- Levodopa is a primary PD treatment, acting as a DA precursor.
Purpose of the Study:
- To investigate the neuroprotective and anti-inflammatory effects of levodopa beyond its role as a dopamine precursor.
- To determine if levodopa can suppress microglial activation and reduce neuroinflammation in a Parkinson's disease model.
Main Methods:
- In vitro: Assessed dopamine's effect on lipopolysaccharide-induced microglial activation in cultured rat microglia.
- In vivo: Administered levodopa to 6-hydroxydopamine (6-OHDA)-induced PD model rats for 7 days.
- Evaluated motor function after a 2-week withdrawal period and measured striatal dopamine levels and microglial activation.
Main Results:
- Dopamine reduced pro-inflammatory reactions and increased tissue-repair factors in cultured microglia.
- Levodopa treatment improved motor function in PD model rats compared to controls.
- Levodopa administration increased striatal dopamine levels and suppressed microglial activation, effects sustained for 2 weeks post-treatment.
Conclusions:
- Levodopa exhibits immunosuppressive properties by reducing microglial activation in the Parkinson's disease brain.
- These findings suggest levodopa has a dual therapeutic action in PD: dopamine replacement and neuroinflammation suppression.
- Levodopa's sustained anti-inflammatory effects may offer long-term benefits for Parkinson's disease patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview
01:37Neural Regulation
01:29Drugs Affecting Neurotransmitter Synthesis